PDT+triamcinolone acetonide = reduced re-treatments

Article

Using photodynamic therapy (PDT) and high-dose intravitreal triamcinolone to treat neovascular age-related macular degeneration (AMD) associated with choroidal neovascularization (CNV) stabilizes vision and reduces the need for re-treatments, according to the results of a study published in the April/May issue of Retina Journal.

Using photodynamic therapy (PDT) and high-dose intravitreal triamcinolone to treat neovascular age-related macular degeneration (AMD) associated with choroidal neovascularization (CNV) stabilizes vision and reduces the need for re-treatments, according to the results of a study published in the April/May issue of Retina Journal.

Jose Ruiz-Moreno and colleagues from the Miguel Hernández University School of Medicine, Alicante, Spain conducted a prospective, consecutive, comparative, non-randomized interventional case series of 30 patients (30 eyes) with subfoveal CNV associated with AMD. Each subject was treated with PDT followed by an intravitreal injection of 19.4±2.1 mg triamcinolone acetonide. Fifteen eyes were naïve to treatment (group 1) while 15 had previously been treated with PDT alone (group 2). Fifteen patients treated with PDT alone served as the control group.

By the two-year follow-up, best corrected visual acuity (BCVA) had not changed significantly in group 1 (0.0±3.4; p=0.81); group 2 had lost and average of -0.6±2.5 lines (p=0.41) and the control group had lost an average of -2.2±3.4 lines. The mean number of PDT sessions during the 24-month follow-up was 1.9, 1.2 and 3.9 for group 1, group 2 and the control group, respectively.

The authors believe that PDT combined with high-dose intravitreal trimacinolone acetonide can help stabilize BCVA and reduce the need for re-treatments.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Related Content
© 2025 MJH Life Sciences

All rights reserved.